Evidence mapPaperPMID 41369373Full record

ReviewCells2025

Mucosal Melanoma: Mechanisms of Its Etiology, Progression, Resistance and Therapy.

Sofie-Yasmin Hassan, Thomas W Flanagan, Sarah-Lilly Hassan, Sybille Facca, Youssef Haikel, Mohamed Hassan

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. A Novel Anti-Cadherin-19 Monoclonal Antibody (CaCurrent issues in molecular biology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sofie-Yasmin HassanPharmacy, Heinrich Heine University Duesseldorf, Universitaetsstr. 1, 40225 Duesseldorf, Germany.
Thomas W FlanaganDepartment of Pharmacology and Experimental Therapeutics, LSU Health Sciences Center, New Orleans, LA 70112, USA.
Sarah-Lilly HassanDepartment of Pharmacy, University of Bonn, An der Immenburg 4, 53121 Bonn, Germany.
Sybille FaccaIcube Laboratory, CNRS, UMR 7357, University of Strasbourg, 67000 Strasbourg, France.
Youssef HaikelInstitut National de la Santé et de la Recherche Médicale, University of Strasbourg, 67000 Strasbourg, France.ORCID 0000-0002-4469-0360
Mohamed HassanInstitut National de la Santé et de la Recherche Médicale, University of Strasbourg, 67000 Strasbourg, France.ORCID 0000-0002-0336-6425

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucosal melanoma (MM) is a rare, aggressive cancer whose incidence has increased continuously over the years. This subtype of melanoma arises from melanocytes on hairless surfaces, typically in the respiratory tract, gastrointestinal (GI) tract, and urogenital tract. The most common sites of occurrence include the head and neck, the anorectal region, and the vulvovaginal region, while the rare sites of MM are the urinary tract and the upper and lower GI tract, including the esophagus, duodenum and the gallbladder. MM arises in melanocytes of the ectodermal mucosa that originate from neural crest cells and migrate through embryonic mesenchyme to their destination. Although melanocytes are located mainly in the epidermis and dermis, their presence in various extracutaneous sites, such as the eyes, mucosal tissue, and leptomeninges, is known. Although both cutaneous melanoma (CM) and MM differ in their epidemiology, genetic profile, and clinical presentation, their treatment options are similar. In contrast to the higher treatment response of CM, MM is characterized by a lower response rate to available treatment options, resulting in a poorer survival rate. In this review, we provide an overview of the biology of MM and the mechanisms regulating its development, progression and treatment resistance.

Indexed as

Disease ProgressionDrug Resistance, NeoplasmMelanomaAnimalsHumansMucous MembraneSignal Transductioncheck point inhibitorsc-Kitimmune therapymelanocytesmucosal melanoma

Identifiers

PMID41369373
PMCPMC12691239

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.